Botulinum neurotoxin to treat chronic anal fissure: Results of a randomized 'Botox vs. Dysport' controlled trial

G. Brisinda, A. Albanese, F. Cadeddu, A. R. Bentivoglio, A. Mabisombi, G. Marniga, G. Maria

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Botulinum neurotoxin induces healing in patients with idiopathic fissure. The optimal dosage is not well established. Aim: To compare the efficacy and tolerability of two different formulations of type A botulinum neurotoxin, and to provide more evidence with regard to the choice of dosage regimens. Methods: Symptomatic adults with chronic anal fissure were enrolled in a randomized study. The outcome of each group was evaluated clinically, and by comparing the pressure of the anal sphincters before and after treatment. Results: Fifty patients received injections of 50 units of Botox formulation (group I), and 50 patients received injections of 150 units of Dysport toxin (group II). One month after injection, 11 patients in group I and eight in group II had mild incontinence of flatus. At the 2-month evaluation point, 46 patients in group I and 47 patients in group II had a healing scar. In group I patients, the mean resting anal pressure was 41.8% lower, and the maximum voluntary squeeze pressure was 20.2% lower, than the baseline value. In group II patients, the resting anal pressure and maximum voluntary squeeze pressure were 60.0 ± 12.0 mmHg and 71.0 ± 30.0 mmHg, respectively. There were no relapses during an average of about 21 months of follow-up. Conclusions: Botulinum neurotoxin may be considered an effective treatment in patients with chronic anal fissure. The efficacy and tolerability of the two different formulations of botulinum neurotoxin were indistinguishable.

Original languageEnglish
Pages (from-to)695-701
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Volume19
Issue number6
DOIs
Publication statusPublished - Mar 15 2004

Fingerprint

Fissure in Ano
Neurotoxins
Pressure
Injections
Flatulence
abobotulinumtoxinA
onabotulinumtoxinA
Anal Canal
Cicatrix
Recurrence

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Botulinum neurotoxin to treat chronic anal fissure : Results of a randomized 'Botox vs. Dysport' controlled trial. / Brisinda, G.; Albanese, A.; Cadeddu, F.; Bentivoglio, A. R.; Mabisombi, A.; Marniga, G.; Maria, G.

In: Alimentary Pharmacology and Therapeutics, Vol. 19, No. 6, 15.03.2004, p. 695-701.

Research output: Contribution to journalArticle

Brisinda, G. ; Albanese, A. ; Cadeddu, F. ; Bentivoglio, A. R. ; Mabisombi, A. ; Marniga, G. ; Maria, G. / Botulinum neurotoxin to treat chronic anal fissure : Results of a randomized 'Botox vs. Dysport' controlled trial. In: Alimentary Pharmacology and Therapeutics. 2004 ; Vol. 19, No. 6. pp. 695-701.
@article{4014ddcf1ab04332bb04f9522a57d7f1,
title = "Botulinum neurotoxin to treat chronic anal fissure: Results of a randomized 'Botox vs. Dysport' controlled trial",
abstract = "Background: Botulinum neurotoxin induces healing in patients with idiopathic fissure. The optimal dosage is not well established. Aim: To compare the efficacy and tolerability of two different formulations of type A botulinum neurotoxin, and to provide more evidence with regard to the choice of dosage regimens. Methods: Symptomatic adults with chronic anal fissure were enrolled in a randomized study. The outcome of each group was evaluated clinically, and by comparing the pressure of the anal sphincters before and after treatment. Results: Fifty patients received injections of 50 units of Botox formulation (group I), and 50 patients received injections of 150 units of Dysport toxin (group II). One month after injection, 11 patients in group I and eight in group II had mild incontinence of flatus. At the 2-month evaluation point, 46 patients in group I and 47 patients in group II had a healing scar. In group I patients, the mean resting anal pressure was 41.8{\%} lower, and the maximum voluntary squeeze pressure was 20.2{\%} lower, than the baseline value. In group II patients, the resting anal pressure and maximum voluntary squeeze pressure were 60.0 ± 12.0 mmHg and 71.0 ± 30.0 mmHg, respectively. There were no relapses during an average of about 21 months of follow-up. Conclusions: Botulinum neurotoxin may be considered an effective treatment in patients with chronic anal fissure. The efficacy and tolerability of the two different formulations of botulinum neurotoxin were indistinguishable.",
author = "G. Brisinda and A. Albanese and F. Cadeddu and Bentivoglio, {A. R.} and A. Mabisombi and G. Marniga and G. Maria",
year = "2004",
month = "3",
day = "15",
doi = "10.1111/j.1365-2036.2004.01895.x",
language = "English",
volume = "19",
pages = "695--701",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Botulinum neurotoxin to treat chronic anal fissure

T2 - Results of a randomized 'Botox vs. Dysport' controlled trial

AU - Brisinda, G.

AU - Albanese, A.

AU - Cadeddu, F.

AU - Bentivoglio, A. R.

AU - Mabisombi, A.

AU - Marniga, G.

AU - Maria, G.

PY - 2004/3/15

Y1 - 2004/3/15

N2 - Background: Botulinum neurotoxin induces healing in patients with idiopathic fissure. The optimal dosage is not well established. Aim: To compare the efficacy and tolerability of two different formulations of type A botulinum neurotoxin, and to provide more evidence with regard to the choice of dosage regimens. Methods: Symptomatic adults with chronic anal fissure were enrolled in a randomized study. The outcome of each group was evaluated clinically, and by comparing the pressure of the anal sphincters before and after treatment. Results: Fifty patients received injections of 50 units of Botox formulation (group I), and 50 patients received injections of 150 units of Dysport toxin (group II). One month after injection, 11 patients in group I and eight in group II had mild incontinence of flatus. At the 2-month evaluation point, 46 patients in group I and 47 patients in group II had a healing scar. In group I patients, the mean resting anal pressure was 41.8% lower, and the maximum voluntary squeeze pressure was 20.2% lower, than the baseline value. In group II patients, the resting anal pressure and maximum voluntary squeeze pressure were 60.0 ± 12.0 mmHg and 71.0 ± 30.0 mmHg, respectively. There were no relapses during an average of about 21 months of follow-up. Conclusions: Botulinum neurotoxin may be considered an effective treatment in patients with chronic anal fissure. The efficacy and tolerability of the two different formulations of botulinum neurotoxin were indistinguishable.

AB - Background: Botulinum neurotoxin induces healing in patients with idiopathic fissure. The optimal dosage is not well established. Aim: To compare the efficacy and tolerability of two different formulations of type A botulinum neurotoxin, and to provide more evidence with regard to the choice of dosage regimens. Methods: Symptomatic adults with chronic anal fissure were enrolled in a randomized study. The outcome of each group was evaluated clinically, and by comparing the pressure of the anal sphincters before and after treatment. Results: Fifty patients received injections of 50 units of Botox formulation (group I), and 50 patients received injections of 150 units of Dysport toxin (group II). One month after injection, 11 patients in group I and eight in group II had mild incontinence of flatus. At the 2-month evaluation point, 46 patients in group I and 47 patients in group II had a healing scar. In group I patients, the mean resting anal pressure was 41.8% lower, and the maximum voluntary squeeze pressure was 20.2% lower, than the baseline value. In group II patients, the resting anal pressure and maximum voluntary squeeze pressure were 60.0 ± 12.0 mmHg and 71.0 ± 30.0 mmHg, respectively. There were no relapses during an average of about 21 months of follow-up. Conclusions: Botulinum neurotoxin may be considered an effective treatment in patients with chronic anal fissure. The efficacy and tolerability of the two different formulations of botulinum neurotoxin were indistinguishable.

UR - http://www.scopus.com/inward/record.url?scp=1842534120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842534120&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2004.01895.x

DO - 10.1111/j.1365-2036.2004.01895.x

M3 - Article

C2 - 15023172

AN - SCOPUS:1842534120

VL - 19

SP - 695

EP - 701

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 6

ER -